-
This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
Tuesday, July 9, 2024 - 7:46am | 450Read More...In Tuesday’s pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders. What Happened: ANEW, a biopharmaceutical company that specializes in...
-
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Tuesday, June 20, 2023 - 5:14pm | 811Read More...In a recent report, Bank of America identified the “Disruptive Dozen” emerging technologies that have the most potential to disrupt and revolutionize the healthcare sector over the next years. New therapy for ALS (amyotrophic lateral sclerosis) and a blood test for Alzheimer’s...
-
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
Wednesday, January 12, 2022 - 6:10pm | 446Read More...PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted an application to proceed with a Phase 2...
-
FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop
Monday, February 22, 2021 - 10:01am | 257Read More...The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently provide the threshold of substantial evidence to support the...
